Investor Relations

The Leader in Brachytherapy

Isoray advances innovative radiotherapeutic technologies that focus on the patient.

Latest Results

Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year   RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Isoray Announces First Quarter Fiscal 2021 Financial Results

Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Research Analyst Coverage

Northland Capital Markets
Tim Chiang

Lake Street Capital Markets, LLC
Frank Takkinen

Oppenheimer & Co.
Suraj Kalia, CFA

Dawson James Securities Inc.
Jason Kolbert

Ascendiant Capital Markets
Edward Woo

 

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Investor Relations:

Mark Levin
Global IR Group
mark@globalirgroup.com

 

Our Management Team

Learn more about our experienced management team who are focused on growth.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.